Gladstone Institutional Advisory LLC Has $806,000 Holdings in Danaher Co. (NYSE:DHR)

Gladstone Institutional Advisory LLC lifted its holdings in Danaher Co. (NYSE:DHR) by 21.8% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,510 shares of the conglomerate’s stock after acquiring an additional 628 shares during the period. Gladstone Institutional Advisory LLC’s holdings in Danaher were worth $806,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of DHR. FMR LLC lifted its holdings in shares of Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after acquiring an additional 3,217,631 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Danaher by 3.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock worth $1,417,342,000 after purchasing an additional 148,251 shares during the last quarter. Fisher Asset Management LLC raised its holdings in Danaher by 2.6% during the 3rd quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock worth $1,265,725,000 after purchasing an additional 116,299 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Danaher by 17.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after purchasing an additional 535,254 shares during the last quarter. Finally, Montrusco Bolton Investments Inc. grew its position in shares of Danaher by 0.6% during the 4th quarter. Montrusco Bolton Investments Inc. now owns 1,715,826 shares of the conglomerate’s stock worth $382,936,000 after buying an additional 9,942 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Price Performance

Shares of DHR stock opened at $203.56 on Friday. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $147.03 billion, a price-to-earnings ratio of 38.55, a P/E/G ratio of 2.68 and a beta of 0.83. Danaher Co. has a twelve month low of $196.80 and a twelve month high of $281.70. The stock has a fifty day simple moving average of $230.49 and a two-hundred day simple moving average of $250.28.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period last year, the firm earned $2.09 EPS. On average, analysts predict that Danaher Co. will post 7.67 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were given a dividend of $0.27 per share. The ex-dividend date was Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.53%. Danaher’s dividend payout ratio is currently 20.45%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on DHR shares. Wells Fargo & Company reduced their price target on shares of Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. TD Cowen raised their price objective on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Barclays lowered their target price on Danaher from $275.00 to $240.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. Robert W. Baird lowered their price objective on Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 28th. Finally, Raymond James reaffirmed a “market perform” rating on shares of Danaher in a report on Monday, February 3rd. Seven equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $278.00.

Insiders Place Their Bets

In related news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 11.10% of the stock is currently owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.